Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Long-term outcomes of CML patients undergoing hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

SRSuravi RaychaudhuriTGTed GooleyCDChris Davis

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals overall survival of 58% in chronic myeloid leukemia patients post-transplant, indicating effectiveness of hematopoietic stem cell transplantation.

Key Points

  • Median overall survival was 179 months with a 10-year OS of 58% for all patients.
  • Risk factors for worse outcomes included positive CMV serostatus and prior blast phase, impacting overall survival.
  • Retrospective evaluation involved patients who received hematopoietic stem cell transplantation and second-generation tyrosine kinase inhibitors.
  • Improved therapy outcomes suggest hematopoietic stem cell transplantation remains a viable option for chronic myeloid leukemia.

Cite This Study

Raychaudhuri et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3f6https://doi.org/10.1182/blood-2025-5556
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia2025
  2. 2Survival impact of post-transplant tyrosine kinase inhibitor therapy in chronic myeloid leukemia.2026
  3. 3Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis2025
  4. 4Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center2025
  5. 5Allogeneic hematopoietic stem cell transplantation for myelofibrosis; Patterns, treatment and outcome after relapse and long-term follow up.2025